Neurocomputational Training to Improve Reward Responsiveness in Veterans With Anhedonia
NCT07928310, Not applicable, Not yet recruiting, VA Office of Research and Development
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Neurocomputational Training to Improve Reward Responsiveness in Veterans With Anhedonia | ClinicalTrials.gov |
| NCT number | NCT07928310 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 120 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | VA Office of Research and Development | ClinicalTrials.gov |
| Conditions | Anhedonia, Depression | ClinicalTrials.gov |
| Interventions | ReLIT (Reward Learning Intensive Training), ST (Sham Training) | ClinicalTrials.gov |
| First posted | 2026-11-10 | ClinicalTrials.gov |
| Last updated | 2026-11-10 | ClinicalTrials.gov |
Registered outcomes 23
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Snaith-Hamilton Pleasure Scale (SHAPS) | Baseline, Post-Treatment (8 weeks), Follow-Up (16 weeks) | Measure of anhedonia. Score range from 14 to 56, with higher scores indicating greater anhedonia severity. | ClinicalTrials.gov |
| Primary | Reward Maximization | Baseline, Post-Treatment (8 weeks), Follow-Up (16 weeks) | Computational parameter derived from participants' choices in a reinforcement learning task, capturing the degree to which individuals select the options they predict to be most rewarding. | ClinicalTrials.gov |
| Primary | Neural Activation to Reward Prediction Errors (RPEs) | Baseline, Post-Treatment (8 weeks) | Average BOLD (Blood-Oxygenation-Level Dependent) % signal change (i.e., activation) associated with individuals' model-based RPE (difference between expected probability of reward and actual outcome received) during reinforcement learning. | ClinicalTrials.gov |
| Secondary | World Health Organization Quality of Life Scale (WHOQOL-BREF) | Baseline, Post-Treatment (8 weeks), Follow-Up (16 weeks) | Measures quality of life and life satisfaction. Includes 4 domain subscales: physical health (range 7-35), psychological health (range 6-30), social relationships (range 3-15), and environment (range 8-42). Higher scores indicate higher quality of life. | ClinicalTrials.gov |
| Secondary | Patient Health Questionnaire-9 (PHQ-9) | Baseline, Post-Treatment (8 weeks), Follow-Up (16 weeks) | Measures depression severity. Scores range from 0 to 27. Higher scores indicate greater depression severity. | ClinicalTrials.gov |
| Secondary | Approach Bias | Baseline, Post-Treatment (8 weeks) | This metric assesses the degree to which individuals display an implicit approach bias towards positive/rewarding cues in an approach-avoidance task. It is computed as the mean response time difference between approach-positive and avoid-positive choices. | ClinicalTrials.gov |
| Secondary | Automatic Positive Affective Processing | Baseline, Post-Treatment (8 weeks) | A measure of implicit bias towards positive relative to negative cues in an affective go/no-go task, as measured but the standardized rate of hits (accurate identification of positive cues) minus standardized rate of false alarms (inaccurate identification of negative cues as positive). | ClinicalTrials.gov |
| Secondary | Neural Activation Associated with Implicit Processing of Positive Cues | Baseline, Post-Treatment (8 weeks) | Average BOLD (Blood-Oxygenation-Level Dependent) % signal change (i.e., activation) associated with the contrast of positive-Go vs negative-Go trials in an affective go/no-go task. | ClinicalTrials.gov |
| Secondary | Neural Activation Associated with Approach Bias | Baseline, Post-Treatment (8 weeks) | Average BOLD (Blood-Oxygenation-Level Dependent) % signal change (i.e., activation) associated with the contrast of (positive-approach vs positive-avoid) minus (neutral-approach vs neutral-avoid) in an approach-avoidance task. | ClinicalTrials.gov |
| Other | Inventory of Psychosocial Functioning (IPF) | Baseline, Post-Treatment (8 weeks), Follow-Up (16 weeks) | The scale measures the degree of impairment in ability to interact effectively with others, fulfill social roles (e.g., work), and meet personal and societal expectations. It is comprised of 7 subscales. Each item ranges from 0 to 6. Higher scores indicate greater degree of impairment in psychosocial functioning. | ClinicalTrials.gov |
| Other | Mood and Anxiety Symptoms Questionnaire (MASQ-D30) | Baseline, Post-Treatment (8 weeks), Follow-Up (16 weeks) | Measure of anhedonic depression, anxiety, and stress symptoms. The scale has three subscales (general distress, anhedonic depression, and anxious arousal) , with each score ranging from 10 to 50. Higher scores indicate greater severity of symptoms. | ClinicalTrials.gov |
| Other | Reaction to Treatment Questionnaire | Baseline, Post-Treatment (8 weeks), Follow-Up (16 weeks) | Measure of treatment satisfaction and credibility of treatment rationale. Total scores range from 3 to 27, with higher scores indicating greater satisfaction and credibility in the treatment. | ClinicalTrials.gov |
| Other | Liebowitz Social Anxiety Scale (LSAS) | Baseline, Post-Treatment (8 weeks), Follow-Up (16 weeks) | Assesses the impact of social anxiety on multiple aspects of life. Scores range from 0 to 144, with higher scores indicating greater social anxiety. | ClinicalTrials.gov |
| Other | Positive and Negative Affect Schedule (PANAS) | Baseline, Post-Treatment (8 weeks), Follow-Up (16 weeks) | Assess positive and negative mood using a 5-point frequency scale (1-5). Each subscale (positive or negative affect) range from 10 to 50. | ClinicalTrials.gov |
| Other | Social Connectedness Scale - Revised (SCS-R) | Baseline, Post-Treatment (8 weeks), Follow-Up (16 weeks) | Measures the degree to which individuals feel connected to others in their social environment. Scores range from 20 to 120, where higher scores indicate a stronger, healthier sense of social connectedness. | ClinicalTrials.gov |
| Other | Foraging Task | Baseline, Post-Treatment (8 weeks) | Measures performance and computational parameters associated with approach and avoidance biases in a dynamic foraging task. | ClinicalTrials.gov |
| Other | Beck Anxiety Inventory (BAI) | Baseline, Post-Treatment (8 weeks), Follow-Up (16 weeks) | This scale measures anxiety severity. Scores range from 0 to 63, with higher scores indicating greater anxiety severity. | ClinicalTrials.gov |
| Other | PTSD Checklist-5 (PCL-5) | Baseline, Post-Treatment (8 weeks), Follow-Up (16 weeks) | Measures post-traumatic stress disorder (PTSD) severity. Scores range from 0 to 80, with higher scores indicating greater PTSD severity. | ClinicalTrials.gov |
| Other | Behavioral Activation for Depression Scale (BADS) | Baseline, Post-Treatment (8 weeks), Follow-Up (16 weeks) | This scale measures changes in activation and avoidance behaviors. Items are measured on a 7-point Likert scale (0-6). Scores range from 0 to 150, with higher scores indicating greater behavioral activation. | ClinicalTrials.gov |
| Other | Quick Structured Clinical Interview for DSM-5 (QuickSCID-5) | Baseline , Post-Treatment (8-weeks) | Measures psychological diagnoses, which will be used to assess primary diagnostic category (i.e., depressive vs traumatic stress/anxiety disorder). | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 4
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Affective Go/No-Go | Secondary outcome | ConductCognition |
| Approach-Avoidance Task | Secondary outcome | ConductCognition |
| Go/No-Go Task | Secondary outcome | ConductCognition |
| Patch Foraging Task | Other outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)